Day 1 - Thursday, 8 November 2018
Meeting category
Date(s)
8 Nov 2018 - 9 Nov 2018
Location
Amsterdam,
Netherlands
Organizer
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Related Enduring Materials
Enduring Materials
Session 1: Pharmacological challenges of immunotherapeutics -
Biomarker in immuno-oncology, are we close? (Not yet available)
Josep María Piulats, MD, PhD
Catalan Institute of Oncology, Spain
Correlation between nivolumab exposure and treatment outcome in NSCLC
Session 2: Dose individualization approaches -
Using pharmacogenetics to improve drug therapy: a 12 year experience with clinical implementation (Not yet available)
Ron van Schaik, PhD, FACB
Erasmus Medical Centre, the Netherlands
Abstract presentation -
A pharmacometric framework for dose individualisation of sunitinib in GIST
Therapeutic drug monitoring as a tool to reduce the occurrence of paclitaxel-associated peripheral neuropathy in patients with advanced NSCLC (Not yet available)
Francis Ojara Williams
#O3
Abstract-driven presentations -
Epigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia
Jason Anderson
USA
Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Wesley Van De Geer
Netherlands
Day 2 - Friday, 9 November 2018
Session 3: Combination therapy – old school is becoming new school again -
Rationale for selecting combinations with immunotherapy
Session 4: Drug-Drug / Drug-Food / Drug-environmental interactions -
Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs)
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS
Abstract presentation -
A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment
A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models
Abstract presentation -
The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants
Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio
Overview
Welcome
We are pleased to look back on a very successful the 3rd International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD), held on the 8th and 9th November 2018 in Amsterdam, the Netherlands.
The Organizing Committee and organizers would like to thank the speakers, chairs and all participants for their contribution to this meeting! Special thanks to the workshop sponsors: Astellas, Pfizer, and BJCP. Without their contribution this workshop would not have been made possible.
We look forward to seeing you again next year at the 4th International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD), tentatively scheduled on 21-22 November 2019, in the Netherlands.
The Organizing Committee
